JP2021036918A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021036918A5 JP2021036918A5 JP2020202687A JP2020202687A JP2021036918A5 JP 2021036918 A5 JP2021036918 A5 JP 2021036918A5 JP 2020202687 A JP2020202687 A JP 2020202687A JP 2020202687 A JP2020202687 A JP 2020202687A JP 2021036918 A5 JP2021036918 A5 JP 2021036918A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- ischemia
- cancer
- ischemic
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 claims 20
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 19
- 230000000302 ischemic effect Effects 0.000 claims 15
- 208000028867 ischemia Diseases 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 10
- 206010008118 cerebral infarction Diseases 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims 7
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims 7
- 208000027418 Wounds and injury Diseases 0.000 claims 7
- 208000029078 coronary artery disease Diseases 0.000 claims 7
- 201000006474 Brain Ischemia Diseases 0.000 claims 6
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 6
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims 6
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims 6
- 201000002818 limb ischemia Diseases 0.000 claims 6
- 210000001519 tissue Anatomy 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 239000007943 implant Substances 0.000 claims 5
- 206010003210 Arteriosclerosis Diseases 0.000 claims 4
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 4
- 208000006011 Stroke Diseases 0.000 claims 4
- 206010052428 Wound Diseases 0.000 claims 4
- 206010069351 acute lung injury Diseases 0.000 claims 4
- 206010000891 acute myocardial infarction Diseases 0.000 claims 4
- 210000001185 bone marrow Anatomy 0.000 claims 4
- 208000026106 cerebrovascular disease Diseases 0.000 claims 4
- 230000014509 gene expression Effects 0.000 claims 4
- 208000030175 lameness Diseases 0.000 claims 4
- 210000000056 organ Anatomy 0.000 claims 4
- 208000033808 peripheral neuropathy Diseases 0.000 claims 4
- 208000011580 syndromic disease Diseases 0.000 claims 4
- 208000019553 vascular disease Diseases 0.000 claims 4
- 208000010392 Bone Fractures Diseases 0.000 claims 3
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims 3
- 206010017076 Fracture Diseases 0.000 claims 3
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 238000002512 chemotherapy Methods 0.000 claims 3
- 230000006378 damage Effects 0.000 claims 3
- 230000007812 deficiency Effects 0.000 claims 3
- 230000003111 delayed effect Effects 0.000 claims 3
- 206010012601 diabetes mellitus Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000014674 injury Diseases 0.000 claims 3
- 230000001400 myeloablative effect Effects 0.000 claims 3
- 208000031225 myocardial ischemia Diseases 0.000 claims 3
- 210000002826 placenta Anatomy 0.000 claims 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 208000031104 Arterial Occlusive disease Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 2
- 208000017234 Bone cyst Diseases 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 208000014644 Brain disease Diseases 0.000 claims 2
- 206010048962 Brain oedema Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 206010007710 Cartilage injury Diseases 0.000 claims 2
- 206010065384 Cerebral hypoperfusion Diseases 0.000 claims 2
- 206010061762 Chondropathy Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 206010010356 Congenital anomaly Diseases 0.000 claims 2
- 208000034656 Contusions Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 206010051055 Deep vein thrombosis Diseases 0.000 claims 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 206010021143 Hypoxia Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 206010022680 Intestinal ischaemia Diseases 0.000 claims 2
- 208000034693 Laceration Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 208000001132 Osteoporosis Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 206010055006 Pancreatic sarcoma Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 206010034576 Peripheral ischaemia Diseases 0.000 claims 2
- 208000037581 Persistent Infection Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000010378 Pulmonary Embolism Diseases 0.000 claims 2
- 206010037423 Pulmonary oedema Diseases 0.000 claims 2
- 206010063897 Renal ischaemia Diseases 0.000 claims 2
- 208000027032 Renal vascular disease Diseases 0.000 claims 2
- 206010063837 Reperfusion injury Diseases 0.000 claims 2
- 208000017442 Retinal disease Diseases 0.000 claims 2
- 206010038923 Retinopathy Diseases 0.000 claims 2
- 206010040047 Sepsis Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 206010040943 Skin Ulcer Diseases 0.000 claims 2
- 206010043540 Thromboangiitis obliterans Diseases 0.000 claims 2
- 208000007536 Thrombosis Diseases 0.000 claims 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 2
- 208000025865 Ulcer Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 206010047249 Venous thrombosis Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 208000006752 brain edema Diseases 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 210000002808 connective tissue Anatomy 0.000 claims 2
- 230000009519 contusion Effects 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 208000009190 disseminated intravascular coagulation Diseases 0.000 claims 2
- 210000004700 fetal blood Anatomy 0.000 claims 2
- 230000035876 healing Effects 0.000 claims 2
- 230000002008 hemorrhagic effect Effects 0.000 claims 2
- 230000000222 hyperoxic effect Effects 0.000 claims 2
- 230000007954 hypoxia Effects 0.000 claims 2
- 208000026278 immune system disease Diseases 0.000 claims 2
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims 2
- 230000004968 inflammatory condition Effects 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 210000003141 lower extremity Anatomy 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 208000025113 myeloid leukemia Diseases 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 201000001119 neuropathy Diseases 0.000 claims 2
- 230000007823 neuropathy Effects 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 201000008968 osteosarcoma Diseases 0.000 claims 2
- 201000002526 pancreas sarcoma Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 210000004738 parenchymal cell Anatomy 0.000 claims 2
- 208000005333 pulmonary edema Diseases 0.000 claims 2
- 238000001959 radiotherapy Methods 0.000 claims 2
- 238000007634 remodeling Methods 0.000 claims 2
- 208000015670 renal artery disease Diseases 0.000 claims 2
- 208000032253 retinal ischemia Diseases 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 231100000019 skin ulcer Toxicity 0.000 claims 2
- 208000020431 spinal cord injury Diseases 0.000 claims 2
- 230000009885 systemic effect Effects 0.000 claims 2
- 210000002435 tendon Anatomy 0.000 claims 2
- 230000001732 thrombotic effect Effects 0.000 claims 2
- 230000000451 tissue damage Effects 0.000 claims 2
- 231100000827 tissue damage Toxicity 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- 230000009529 traumatic brain injury Effects 0.000 claims 2
- 231100000397 ulcer Toxicity 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- 208000006542 von Hippel-Lindau disease Diseases 0.000 claims 2
- 230000029663 wound healing Effects 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000032467 Aplastic anaemia Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 102100025621 Cytochrome b-245 heavy chain Human genes 0.000 claims 1
- 206010016717 Fistula Diseases 0.000 claims 1
- 208000018565 Hemochromatosis Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 208000002678 Mucopolysaccharidoses Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 208000008601 Polycythemia Diseases 0.000 claims 1
- 208000009527 Refractory anemia Diseases 0.000 claims 1
- 206010072684 Refractory cytopenia with unilineage dysplasia Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 230000001919 adrenal effect Effects 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 208000021328 arterial occlusion Diseases 0.000 claims 1
- 208000022806 beta-thalassemia major Diseases 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 210000000601 blood cell Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 238000002659 cell therapy Methods 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000016532 chronic granulomatous disease Diseases 0.000 claims 1
- 201000005483 chronic intestinal vascular insufficiency Diseases 0.000 claims 1
- 210000004351 coronary vessel Anatomy 0.000 claims 1
- 229910003460 diamond Inorganic materials 0.000 claims 1
- 239000010432 diamond Substances 0.000 claims 1
- 230000003073 embolic effect Effects 0.000 claims 1
- 230000002449 erythroblastic effect Effects 0.000 claims 1
- 230000003890 fistula Effects 0.000 claims 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 1
- 235000015110 jellies Nutrition 0.000 claims 1
- 239000008274 jelly Substances 0.000 claims 1
- 230000000366 juvenile effect Effects 0.000 claims 1
- 206010028093 mucopolysaccharidosis Diseases 0.000 claims 1
- 230000002107 myocardial effect Effects 0.000 claims 1
- 230000000422 nocturnal effect Effects 0.000 claims 1
- 230000000242 pagocytic effect Effects 0.000 claims 1
- 230000001314 paroxysmal effect Effects 0.000 claims 1
- 210000005259 peripheral blood Anatomy 0.000 claims 1
- 239000011886 peripheral blood Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 206010043554 thrombocytopenia Diseases 0.000 claims 1
- 201000010875 transient cerebral ischemia Diseases 0.000 claims 1
- 230000001052 transient effect Effects 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161566492P | 2011-12-02 | 2011-12-02 | |
| US61/566,492 | 2011-12-02 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019113661A Division JP2019187429A (ja) | 2011-12-02 | 2019-06-19 | 増強された幹細胞組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021036918A JP2021036918A (ja) | 2021-03-11 |
| JP2021036918A5 true JP2021036918A5 (https=) | 2021-07-26 |
Family
ID=48536037
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014544868A Active JP6220791B2 (ja) | 2011-12-02 | 2012-11-29 | 増強された幹細胞組成物 |
| JP2017098749A Active JP6483187B2 (ja) | 2011-12-02 | 2017-05-18 | 増強された幹細胞組成物 |
| JP2018244311A Active JP6775568B2 (ja) | 2011-12-02 | 2018-12-27 | 増強された幹細胞組成物 |
| JP2019113661A Withdrawn JP2019187429A (ja) | 2011-12-02 | 2019-06-19 | 増強された幹細胞組成物 |
| JP2020202687A Pending JP2021036918A (ja) | 2011-12-02 | 2020-12-07 | 増強された幹細胞組成物 |
| JP2021156680A Pending JP2021191311A (ja) | 2011-12-02 | 2021-09-27 | 増強された幹細胞組成物 |
| JP2023017468A Pending JP2023053019A (ja) | 2011-12-02 | 2023-02-08 | 増強された幹細胞組成物 |
Family Applications Before (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014544868A Active JP6220791B2 (ja) | 2011-12-02 | 2012-11-29 | 増強された幹細胞組成物 |
| JP2017098749A Active JP6483187B2 (ja) | 2011-12-02 | 2017-05-18 | 増強された幹細胞組成物 |
| JP2018244311A Active JP6775568B2 (ja) | 2011-12-02 | 2018-12-27 | 増強された幹細胞組成物 |
| JP2019113661A Withdrawn JP2019187429A (ja) | 2011-12-02 | 2019-06-19 | 増強された幹細胞組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021156680A Pending JP2021191311A (ja) | 2011-12-02 | 2021-09-27 | 増強された幹細胞組成物 |
| JP2023017468A Pending JP2023053019A (ja) | 2011-12-02 | 2023-02-08 | 増強された幹細胞組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US9452186B2 (https=) |
| EP (2) | EP3785767A1 (https=) |
| JP (7) | JP6220791B2 (https=) |
| CN (3) | CN112375734A (https=) |
| AU (1) | AU2012321088B8 (https=) |
| CA (1) | CA2857640C (https=) |
| ES (1) | ES2836976T3 (https=) |
| PT (1) | PT2785834T (https=) |
| WO (1) | WO2013082243A1 (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3785767A1 (en) * | 2011-12-02 | 2021-03-03 | Fate Therapeutics, Inc. | Enhanced stem cell composition |
| US10111907B2 (en) | 2011-12-02 | 2018-10-30 | Fate Therapeutics, Inc. | Methods of treating ischemia |
| US9801863B2 (en) | 2012-04-16 | 2017-10-31 | Case Western Reserve University | Inhibitors of short-chain dehydrogenase activity for modulating hematopoietic stem cells and hematopoiesis |
| DK2838533T3 (da) | 2012-04-16 | 2017-11-27 | Univ Case Western Reserve | Sammensætninger og fremgangsmåder til at modulere 15-pgdh-aktivitet |
| US9943545B2 (en) | 2013-03-15 | 2018-04-17 | Fate Therapeutics, Inc. | Stem cell culture media and methods of enhancing cell survival |
| US10851412B2 (en) | 2013-03-15 | 2020-12-01 | Fate Therapeutics, Inc. | Cell potency assay for therapeutic potential |
| AU2014342811B2 (en) | 2013-10-15 | 2019-01-03 | Board Of Regents Of The University Of Texas System | Compositions and methods of modulating short-chain dehydrogenase activity |
| EP3104867B1 (en) * | 2014-02-12 | 2022-01-19 | 7 Hills Pharma LLC | Compositions and methods to improve the homing and grafting of hematopoetic stem cells |
| US20180112180A1 (en) * | 2015-01-26 | 2018-04-26 | Fate Therapeutics, Inc. | Cells with increased immuno-regulatory properties and methods for their use and manufacture |
| AU2016211671B2 (en) | 2015-01-26 | 2022-05-26 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
| CN118059093A (zh) | 2015-03-08 | 2024-05-24 | 卡斯西部储备大学 | 用于治疗纤维症的短链脱氢酶活性的抑制剂 |
| RU2018106515A (ru) | 2015-07-21 | 2019-08-21 | Зе Чилдрен'С Медикал Сентер Корпорейшн | Pd-l1-экспрессирующие гемопоэтические стволовые клетки и применения |
| WO2017059281A1 (en) * | 2015-10-02 | 2017-04-06 | Mcquillan Sharon Patrica | Adipose-derived stem cell product |
| JP6928604B2 (ja) | 2015-11-04 | 2021-09-01 | フェイト セラピューティクス，インコーポレイテッド | 万能性細胞のゲノム改変 |
| CA3003152A1 (en) | 2015-11-04 | 2017-05-11 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
| EP3510145A4 (en) | 2016-09-06 | 2020-03-25 | The Children's Medical Center Corporation | IMMUNCELLS FROM INDUCED PLURIPOTENT STEM CELLS |
| WO2018070819A1 (ko) * | 2016-10-14 | 2018-04-19 | 제주대학교 산학협력단 | 시클레소나이드를 포함하는, 암 줄기세포 성장 억제용 조성물 |
| JP7595413B2 (ja) | 2016-11-30 | 2024-12-06 | ケース ウエスタン リザーブ ユニバーシティ | １５－ｐｇｄｈ阻害剤とコルチコステロイドおよび／またはｔｎｆ阻害剤との組み合わせならびにその使用 |
| WO2018145080A1 (en) | 2017-02-06 | 2018-08-09 | Case Western Reserve University | Compositions and methods of modulating short-chain dehydrogenase activity |
| WO2019060708A1 (en) | 2017-09-22 | 2019-03-28 | The Children's Medical Center Corporation | TREATMENT OF TYPE 1 DIABETES AND AUTOIMMUNE DISEASES OR DISORDERS |
| US11285177B2 (en) | 2018-01-03 | 2022-03-29 | Globus Medical, Inc. | Allografts containing viable cells and methods thereof |
| JP7524157B2 (ja) | 2018-07-22 | 2024-07-29 | ミノヴィア セラピューティクス リミテッド | 脳疾患のミトコンドリア増強療法 |
| WO2020021536A1 (en) | 2018-07-22 | 2020-01-30 | Minovia Therapeutics Ltd. | Mitochondrial augmentation therapy for primary mitochondrial diseases |
| JP2021531288A (ja) | 2018-07-22 | 2021-11-18 | ミノヴィア セラピューティクス リミテッド | 眼疾患のミトコンドリア増強療法 |
| US12551504B2 (en) | 2018-07-22 | 2026-02-17 | Minovia Therapeutics Ltd. | Mitochondrial augmentation therapy of pancreatic diseases |
| US12329781B2 (en) | 2018-07-22 | 2025-06-17 | Minovia Therapeutics Ltd. | Mitochondrial augmentation therapy of renal diseases |
| CN120463721A (zh) | 2018-11-21 | 2025-08-12 | 卡斯西部储备大学 | 调节短链脱氢酶活性的组合物和方法 |
| CA3172402A1 (en) | 2020-03-31 | 2021-10-07 | Minovia Therapeutics Ltd. | Mitochondria-enriched genetically engineered cells and uses thereof |
| CN113069460B (zh) * | 2021-03-24 | 2022-02-08 | 兰州大学 | 哈西奈德及其衍生物用于制备治疗和/或预防脑血管疾病药物中的应用 |
| CN114848675A (zh) * | 2022-06-24 | 2022-08-05 | 南开大学 | Pge2赋能的间充质干细胞制剂在制备治疗肺损伤药物中的应用 |
| GB202211232D0 (en) | 2022-08-02 | 2022-09-14 | Heptares Therapeutics Ltd | Prostaglandin EP4 receptor agonist compounds |
| WO2025155768A1 (en) * | 2024-01-17 | 2025-07-24 | Rhode Island Hospital | A motile injectable cell that accelerates musculoskeletal connective tissue repair |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4839032B1 (https=) | 1964-09-11 | 1973-11-21 | ||
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5077049A (en) | 1989-07-24 | 1991-12-31 | Vipont Pharmaceutical, Inc. | Biodegradable system for regenerating the periodontium |
| SG59931A1 (en) | 1989-10-16 | 1999-02-22 | Amgen Inc | Stem cell factor |
| US5061620A (en) | 1990-03-30 | 1991-10-29 | Systemix, Inc. | Human hematopoietic stem cell |
| US5635387A (en) | 1990-04-23 | 1997-06-03 | Cellpro, Inc. | Methods and device for culturing human hematopoietic cells and their precursors |
| AU2882992A (en) | 1991-11-06 | 1993-06-07 | Arthur A. Axelrad | Cell culture medium |
| JP2795014B2 (ja) | 1991-11-29 | 1998-09-10 | 東洋インキ製造株式会社 | 保存温度管理用インジケーター |
| US5460964A (en) | 1992-04-03 | 1995-10-24 | Regents Of The University Of Minnesota | Method for culturing hematopoietic cells |
| US5442033A (en) | 1993-07-20 | 1995-08-15 | Ethicon, Inc. | Liquid copolymers of epsilon-caprolactone and lactide |
| AU702871B2 (en) | 1993-08-23 | 1999-03-11 | Nexell Therapeutics Inc. | (In vitro) growth of neutrophil and megakaryocyte precursors in serum-free media |
| US5409813A (en) | 1993-09-30 | 1995-04-25 | Systemix, Inc. | Method for mammalian cell separation from a mixture of cell populations |
| US5648331A (en) | 1994-08-26 | 1997-07-15 | G.D. Searle & Co. | Method of inhibiting tissue ischemia and reperfusion injury |
| US5677136A (en) | 1994-11-14 | 1997-10-14 | Systemix, Inc. | Methods of obtaining compositions enriched for hematopoietic stem cells, compositions derived therefrom and methods of use thereof |
| US5753516A (en) | 1995-02-03 | 1998-05-19 | Heagy; Wyrta E. | Screening method for ligands of the EBI-1 receptor |
| WO1996040866A1 (en) | 1995-06-07 | 1996-12-19 | Novartis Ag | Serum-free media for primitive hematopoietic cells and methods of use thereof |
| US5709472A (en) | 1995-10-23 | 1998-01-20 | Lifelines Technology, Inc. | Time-temperature indicator device and method of manufacture |
| US5854033A (en) | 1995-11-21 | 1998-12-29 | Yale University | Rolling circle replication reporter systems |
| US5945337A (en) | 1996-10-18 | 1999-08-31 | Quality Biological, Inc. | Method for culturing CD34+ cells in a serum-free medium |
| US6372796B1 (en) | 1996-11-13 | 2002-04-16 | Cold Spring Harbor Laboratory | Therapeutic uses for nitric oxide inhibitors |
| US6191109B1 (en) | 1997-10-31 | 2001-02-20 | Children's Hospital, Inc. | Methods of treating intestinal ischemia using heparin-binding epidermal growth factor |
| DE69817995T2 (de) | 1998-01-05 | 2004-07-22 | Mitra Industries Ltd. | Flexibler, zusammenfaltbarer Blutbeutel |
| IL125532A0 (en) * | 1998-07-27 | 1999-03-12 | Yeda Res & Dev | Hematopoietic cell composition for use in transplantation |
| AU2183900A (en) | 1998-12-24 | 2000-07-31 | Alcon Laboratories, Inc. | Ep4 receptor agonists for treatment of dry eye |
| US6946293B1 (en) | 1999-02-10 | 2005-09-20 | Es Cell International Pte Ltd. | Progenitor cells, methods and uses related thereto |
| GB9904281D0 (en) | 1999-02-24 | 1999-04-21 | Reneuron Ltd | Transplantation |
| AU770867B2 (en) | 1999-08-13 | 2004-03-04 | Fumie Sato | Prostaglandin derivatives |
| BR0015781A (pt) | 1999-11-24 | 2002-12-31 | Ono Pharmaceutical Co | Composição farmacêutica para tratamento de doenças associadas à diminuição de massa óssea |
| TWI247606B (en) | 1999-11-24 | 2006-01-21 | Ono Pharmaceutical Co | Treating agent for osteopenic diseases |
| IL141120A0 (en) | 2000-01-31 | 2002-02-10 | Pfizer Prod Inc | Use of prostaglandin (pge2) receptor 4 (epa) selective agonists for the treatment of acute and chronic renal failure |
| US20020013294A1 (en) | 2000-03-31 | 2002-01-31 | Delong Mitchell Anthony | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
| FR2825261B1 (fr) | 2001-06-01 | 2003-09-12 | Maco Pharma Sa | Ligne de prelevement du sang placentaire comprenant une poche de rincage |
| US7179643B2 (en) | 2001-06-14 | 2007-02-20 | Reliance Life Sciences Pvt. Ltd. | Device and a process for expansion of haemopoeitic stem cells for therapeutic use |
| EP1458854B1 (en) | 2001-12-21 | 2010-04-14 | Mount Sinai Hospital | Cellular compositions and methods of making and using them |
| EP1348758A1 (en) * | 2002-03-28 | 2003-10-01 | Boehringer Ingelheim Pharma GmbH & Co.KG | Host cells having improved cell survival properties and methods to generate such cells |
| RU2205627C1 (ru) | 2002-05-30 | 2003-06-10 | Открытое акционерное общество "Косметическое объединение "Свобода" | Крем для лица, выводящий токсины |
| ES2584606T3 (es) | 2002-10-10 | 2016-09-28 | Ono Pharmaceutical Co., Ltd. | Microesferas que comprenden ONO-1301 |
| NZ541828A (en) | 2003-03-04 | 2008-06-30 | Pfizer Prod Inc | Use of EP2 selective receptor agonists in medical treatment |
| US20050054103A1 (en) | 2003-03-07 | 2005-03-10 | Tony Peled | Expansion of renewable stem cell populations using modulators of PI 3-kinase |
| AU2004219595A1 (en) | 2003-03-11 | 2004-09-23 | Qlt Usa Inc. | Formulations for cell- schedule dependent anticancer agents |
| AU2004227205B2 (en) | 2003-04-08 | 2010-06-10 | Yeda Research And Development Co. Ltd | Stem cells having increased sensitivity to a chemoattractant and methods of generating and using same |
| US6747037B1 (en) | 2003-06-06 | 2004-06-08 | Allergan, Inc. | Piperidinyl prostaglandin E analogs |
| US8309608B2 (en) | 2003-11-06 | 2012-11-13 | Sanofi-Aventis Deutschland Gmbh | Use of eNOS transcription enhancers in the cell therapy of ischemic heart diseases |
| IL158868A0 (en) * | 2003-11-13 | 2004-05-12 | Yeda Res & Dev | Methods of generating and using stem cells enriched with immature primitive progenitor |
| CA2535169A1 (en) | 2003-12-31 | 2005-07-21 | Osteotech, Inc. | Improved bone matrix compositions and methods |
| US20070204351A1 (en) | 2004-01-14 | 2007-08-30 | Davidson Bruce P | Direct differentiation of cardiomyocytes from human embryonic stem cells |
| JP2005220089A (ja) | 2004-02-06 | 2005-08-18 | Menicon Co Ltd | 組織等価物用パッケージ |
| US20050176140A1 (en) | 2004-02-10 | 2005-08-11 | Benedict Daniel J. | Method and apparatus for cell culture using a two liquid phase bioreactor |
| US7004621B2 (en) | 2004-06-17 | 2006-02-28 | Cryovac, Inc. | Method of monitoring temperature exposure |
| JP4086816B2 (ja) | 2004-07-01 | 2008-05-14 | 株式会社Ｎｅｃ情報システムズ | Ｂｇａ部品搭載基板の層数見積もり装置及び方法並びに層数見積もりプログラム |
| US7147626B2 (en) | 2004-09-23 | 2006-12-12 | Celgene Corporation | Cord blood and placenta collection kit |
| KR20070085288A (ko) * | 2004-09-24 | 2007-08-27 | 안지오블라스트 시스템스 인코퍼레이티드 | 간엽 전구세포의 증식 및/또는 생존성 증강 방법 |
| CN105168250B (zh) * | 2004-10-25 | 2019-02-05 | 塞勒兰特治疗公司 | 增殖骨髓细胞群体的方法及其应用 |
| AU2005299473B2 (en) | 2004-10-26 | 2012-06-28 | Allergan, Inc. | Therapeutic and delivery methods of prostaglandin EP4 agonists |
| WO2006078886A2 (en) | 2005-01-18 | 2006-07-27 | Irm Llc | Compounds and compositions as wnt signaling pathway modulators |
| EP2428563A1 (en) | 2005-02-10 | 2012-03-14 | Regents Of The University Of Minnesota | Vascular/lymphatic endothelial cells |
| JP4839032B2 (ja) * | 2005-07-13 | 2011-12-14 | 国立大学法人 岡山大学 | ケモカイン受容体作用増強剤 |
| CA2628865A1 (en) | 2005-11-07 | 2007-05-18 | The General Hospital Corporation | Methods and compositions for modulation of stem cell aging |
| DE102005062741A1 (de) | 2005-12-22 | 2007-06-28 | Bayer Schering Pharma Ag | Fluorene und Carbazole als Liganden des EP2 Rezeptors |
| WO2007092585A2 (en) | 2006-02-08 | 2007-08-16 | Becton, Dickinson And Company | Biological specimen collection and storage devices |
| EP3424507A1 (en) | 2006-03-24 | 2019-01-09 | Children's Medical Center Corporation | Method to modulate hematopoietic stem cell growth |
| JP5254226B2 (ja) | 2006-07-14 | 2013-08-07 | エクセレレックス インク． | 環境保護用収容システム |
| US20100233135A1 (en) | 2006-08-16 | 2010-09-16 | The General Hospital Corporation | Compositions and methods for hematopoietic stem cell expansion or for modulating angiogenesis |
| WO2008056963A1 (en) | 2006-11-10 | 2008-05-15 | Chanil Moon | Method for proliferating stem cells with leptin |
| US9394520B2 (en) | 2006-12-08 | 2016-07-19 | University Of Rochester | Expansion of hematopoietic stem cells |
| US8871752B2 (en) | 2008-02-19 | 2014-10-28 | Sucampo Ag | Method for modulating stem cell growth |
| WO2009134532A2 (en) | 2008-03-07 | 2009-11-05 | The Trustees Of Columbia University In The City Of New York | Homing in mesenchymal stem cells |
| PT3031907T (pt) * | 2008-11-06 | 2021-01-28 | Univ Indiana Res & Tech Corp | Materiais e métodos para melhorar procedimentos de enxerto de células estaminais hematopoiéticas |
| CN102245189B (zh) | 2008-12-03 | 2015-06-17 | 阿莫塞特公司 | 改善梗死区灌注的组合物以及血管损伤修复方法 |
| EP2408444A4 (en) | 2009-03-19 | 2012-09-26 | Fate Therapeutics Inc | COMPOSITIONS WITH CYCLIC AMP AMPLIFIERS AND / OR EP LIGANDS, AND METHOD FOR THEIR PRODUCTION AND USE |
| EP2275442A1 (en) * | 2009-07-06 | 2011-01-19 | Ludwig-Maximilians-Universität München | Detection and vizualization of the cell cycle in living cells |
| EP2603227B1 (en) | 2010-08-12 | 2017-10-04 | Fate Therapeutics, Inc. | Improved hematopoietic stem and progenitor cell therapy |
| EP3785767A1 (en) | 2011-12-02 | 2021-03-03 | Fate Therapeutics, Inc. | Enhanced stem cell composition |
| US10111907B2 (en) | 2011-12-02 | 2018-10-30 | Fate Therapeutics, Inc. | Methods of treating ischemia |
-
2012
- 2012-11-29 EP EP20197373.2A patent/EP3785767A1/en not_active Withdrawn
- 2012-11-29 CN CN202011283996.3A patent/CN112375734A/zh active Pending
- 2012-11-29 JP JP2014544868A patent/JP6220791B2/ja active Active
- 2012-11-29 AU AU2012321088A patent/AU2012321088B8/en active Active
- 2012-11-29 CN CN202011283992.5A patent/CN112410298A/zh active Pending
- 2012-11-29 US US14/362,386 patent/US9452186B2/en active Active
- 2012-11-29 ES ES12854238T patent/ES2836976T3/es active Active
- 2012-11-29 CN CN201280067558.0A patent/CN104066837B/zh active Active
- 2012-11-29 EP EP12854238.8A patent/EP2785834B1/en active Active
- 2012-11-29 WO PCT/US2012/066987 patent/WO2013082243A1/en not_active Ceased
- 2012-11-29 PT PT128542388T patent/PT2785834T/pt unknown
- 2012-11-29 CA CA2857640A patent/CA2857640C/en active Active
-
2016
- 2016-09-02 US US15/256,133 patent/US10172888B2/en active Active
-
2017
- 2017-05-18 JP JP2017098749A patent/JP6483187B2/ja active Active
-
2018
- 2018-12-12 US US16/218,314 patent/US11052118B2/en active Active
- 2018-12-27 JP JP2018244311A patent/JP6775568B2/ja active Active
-
2019
- 2019-06-19 JP JP2019113661A patent/JP2019187429A/ja not_active Withdrawn
-
2020
- 2020-12-07 JP JP2020202687A patent/JP2021036918A/ja active Pending
-
2021
- 2021-06-04 US US17/339,440 patent/US20220118021A1/en not_active Abandoned
- 2021-09-27 JP JP2021156680A patent/JP2021191311A/ja active Pending
-
2023
- 2023-02-08 JP JP2023017468A patent/JP2023053019A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021036918A5 (https=) | ||
| JP2019187429A5 (https=) | ||
| JP2015504313A5 (https=) | ||
| JP6775568B2 (ja) | 増強された幹細胞組成物 | |
| Paschalaki et al. | Recent advances in endothelial colony forming cells toward their use in clinical translation | |
| Banno et al. | Tissue regeneration using endothelial colony-forming cells: promising cells for vascular repair | |
| Patel et al. | The role of endothelial cells and their progenitors in intimal hyperplasia | |
| Penn et al. | Role of stem cell homing in myocardial regeneration | |
| JP2015505829A5 (https=) | ||
| CN102920734A (zh) | 一种间充质干细胞注射液及其制备方法和在制备治疗溃疡性结肠炎药物中的应用 | |
| Barboni et al. | Placental stem cells from domestic animals: translational potential and clinical relevance | |
| US20100068190A1 (en) | Mesoangioblast-like cell as well as methods and uses relating thereto | |
| Selem et al. | Stem cell therapy for pediatric dilated cardiomyopathy | |
| Park et al. | Perioperative red blood cell transfusion in orofacial surgery | |
| Anwar et al. | Therapeutic potential of umbilical cord stem cells for liver regeneration | |
| Pytlík et al. | Efficacy and safety of human mesenchymal stromal cells in healing of critical-size bone defects in immunodeficient rats | |
| Kwiatkowski et al. | Combined intra-arterial and intra-muscular transfer of Wharton’s jelly mesenchymal stem/stromal cells in no-option critical limb ischemia–the CIRCULATE NO CLI Pilot Study | |
| Hassanpour et al. | Current status of cardiac regenerative medicine; An update on point of view to cell therapy application | |
| Lecorgne et al. | Mesenchymal Stem Cells and PRP combined therapy promotes gastric leak closure following sleeve gastrectomy | |
| Can et al. | Mesenchymal stem/stromal cells from neonatal tissues | |
| CN108315293A (zh) | 一种血管内皮祖细胞的制备方法 | |
| Zheng et al. | Stem cell therapy in pulmonary arterial hypertension: current practice and future opportunities | |
| Keighron et al. | Progenitor Cells Toward Their Use in | |
| Gorjipour et al. | Fetal adnexa-derived allogeneic mesenchymal stem cells for cardiac regeneration: the future trend of cell-based therapy for age-related adverse conditions | |
| Lima et al. | The use of mesenchymal stem cells in the treatment of osteogenesis imperfecta: An integrative and qualitative review of literature |